Suchergebnisse - "Xing, Haiyan"

PubPharm (166)

1

CXCR6 defines therapeutic subtypes of CD4+ cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia

enthalten in: International immunopharmacology | 2024

von Shi, S. | Xing, H. | Xu, X. | +4

2

The Application Value of CICARE Communication Mode Combined with Detailed Nursing on the Related Factors of Poor Prognosis of Patients After Gastric Cancer Resection

enthalten in: Alternative therapies in health and medicine | 2024

von Xu, S. | Huang, L. | Xing, H. | +3

3

A dual-targeting approach with anti-IL10R CAR-T cells engineered to release anti-CD33 bispecific antibody in enhancing killing effect on acute myeloid leukemia cells

enthalten in: ResearchSquare.com | 2024

von Yan, Z. | Gu, R. | Chen, N. | +10

4

Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells

enthalten in: Human gene therapy | 2023

von Xie, L. | Gu, R. | Yang, X. | +10

5

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity

enthalten in: Cancer communications (London, England) | 2023

von Wang, Z. | Lu, Y. | Liu, Y. | +15

6

2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway

enthalten in: Cytotherapy | 2023

von Mou, J. | Xie, L. | Xu, Y. | +10

7

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

enthalten in: Experimental hematology & oncology | 2023

von Chen, M. | Liu, X. | Peng, N. | +13

8

Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

enthalten in: Experimental hematology & oncology | 2023

von Chen, M. | Liu, X. | Peng, N. | +13

9

Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently

enthalten in: Science China. Life sciences | 2023

von Chen, Z. | Liu, Y. | Chen, N. | +8

10

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China

enthalten in: Frontiers in immunology | 2023

von Xiang, G. | Jiang, T. | Gan, L. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]